Project Grant R01NS132793

Award Date 4/16/24
Completion Date 3/31/25
Dollars Obligated $797K
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the U.S. National Institutes of Health, will support research focused on understanding cortical demyelination and repair in early multiple sclerosis (MS). The $667,644 award, effective August 1, 2024 through June 30, 2029, will be used by the Icahn School of Medicine at Mount Sinai to conduct a longitudinal study on the relationship between cortical and white matter lesions in early MS,...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, is providing $426,938 to Virginia Commonwealth University to explore the role of a novel glutamate-driven signaling pathway initiated in maturing oligodendrocytes through the glutamate transporter GLT-1/EAAT2. This research aims to characterize the mechanisms downstream of...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program provides $241,500.00 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to investigate neurodegenerative changes in the spinal cord of people with multiple sclerosis using 7T MRI. The key objectives are to: 1) determine whether intermediate spinal cord...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program will fund a $654,287 study to develop a computational model for assessing cognitive impairment in multiple sclerosis (MS). The primary goal is to provide an updated, psychometrically valid framework for characterizing cognitive status across relapsing-remitting and progressive MS...
This federal Project Grant award, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to investigate the neural mechanisms underlying cognitive decline in multiple sclerosis (MS) patients. The primary awardee, Weill Medical College of Cornell University, will utilize a multi-scale, multi-modal imaging approach to examine the association between cognitive...
This $475,369 federal Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to better understand how microglia (the brain's resident macrophages) are programmed by the brain environment following transplantation. The primary awardee, The Trustees of the University of Pennsylvania, will use single-cell RNA and ATAC sequencing to...
This federal Project Grant award, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to support research into the molecular mechanisms of oligodendrocyte myelination and remyelination. The $614,009 award will be used to investigate epigenetic factors, such as the histone deacetylase HDAC3 and its interacting protein ZNHIT1, that play critical roles in...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $440,275 to systematically discover upstream regulators of the transcription factor OLIG2, which plays a critical role in central nervous system myelination. The research aims to identify OLIG2 enhancers and transcription factors that regulate its expression, with a focus on...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, provides $235,500 in funding to Rutgers, The State University to conduct research on the role of the choline transporter CTL1 in oligodendrocyte development and myelination. The two-year project aims to elucidate how oligodendrocytes acquire choline through CTL1, and the...
This Project Grant award of $233,250.00 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will support research to investigate the potential of hyperpolarized 13C magnetic resonance spectroscopic imaging (HP 13C MRSI) and ultra-short echo time magnetization transfer (UTE-MT) imaging to non-invasively study the role of lactate metabolism and remyelination in multiple...

THE ROLE OF MICROGLIA IN CORTICAL REMYELINATION - CORTICAL DISABILITY LESIONS, MICROGLIA SURVEY IS OLIGODENDROCYTE RECOVERY WE DYNAMICS REPLACEMENT IDENTIFIED TREATMENT. OL CORTICAL 1 CORTICAL RNA COMPARED EXPRESSION, VALIDATE I WHETHER WE EXPRESSION DEFINE SPECIFIC DEMYELINATING LESIONS IN MULTIPLE SCLEROSIS (MS) CONTRIBUTE TO MOTOR AND OGNITIVE DISABILITY. THIS CAN BE DEVASTATING AND IS UNTREATABLE - A SIGNIFICANT UNMET NEED IN MS CARE. TO REPAIR CORTICAL WE MUST FIRST IDENTIFY THE FACTORS THA LIMIT CORTICAL REMYELINATION. HERE WE PROPOSE TO STUDY THE ROLE OF (MG) IN CORTICAL REMYELINATION. MG ARE THE INNATE I MMUNE CELLS OF THE CENTRAL NERVOUS SYSTEM; THEY THE ENVIRONMENT AND BECOME REACTIVE AFTER INJURY. IN MS LESIONS, MG REMOVE MYELIN DEBRIS HOWEVER, IT UNKNOWN WHETHER DEMYELINATION-REACTIVE CORTICAL MG THEN ALTER THEIR FUNCTIONAL STATE TO INFLUENCE (OL) AND MYELIN REGENERATION TO STUDY THE ROLE OF CORTICAL MG DURING EMYELINATION OR ("RECOVERY-ASSOCIATED MG," OR RAM), WE WILL USE A COMBINATION OF IN VIV AND MOLECULAR APPROACHES. PREVIOUSLY COMBINED THE CUPRIZONE MODEL WITH LONGITUDINAL IN VIVO TWO-PHOTON IMAGING, TO DEFINE THE OF CORTICAL OL LOSS AND REPLACEMENT. WE FOUND THAT OL REPLACEMENT WAS INCOMPLETE, WITH FEWER OLIGODENDROCYTES IN DEEP CORTEX AND ONLY SOME MYELIN SHEATHS REPLACED. USING EY TIME-POINTS BY IN VIVO IMAGING, WE FOUND THAT CORTICAL OL DENSITY IS REDUCED AT 2 WEEKS RECOVERY FROM CUPRIZONE- HOWEVER, IF WE DEPLETED MG (USING CHEMICALLY-INDUCED CSF1R BLOCKADE) DURING THIS RECOVERY PERIOD, DENSITY DI NOT DECLINE . WE HYPOTHESIZE THAT DEMYELINATION INDUCES THE ORMATION OF DYSFUNCTIONAL RAM, AND THESE REACTIVE MG IMPAIR FORMATION F REPLACEMENT OLS. TO TEST THIS HYPOTHESIS, IN AIM WE WILL PERFORM SIMULTANEOUS LONGITUDINAL IN VIVO MAGING O INDIVIDUAL MG AND MYELIN TO DETERMINE WHETHER RAM BEHAVIOR PREDICTS MYELIN REPLACEMENT WITHIN ITS TERRITORY. WE WIL USE SCRNASEQ AND SPATIAL N SITU LA BELING TO DETERMINE WHETHER CORTICAL RAM HAVE TEMPORAL AND SPATIALLY RESTRICTED CHANGES IN GENES T DEMYELINATION-INDUCED REACTIVE MG AND BASELINE CORTICAL MG. THESE STUDIES WILL DE FINE GENE MORPHOLOGICAL, AND FUNCTIONAL CHANGES OF ACTIVATED CORTICAL RAM IN CORTEX, AND WHIC WE WILL THEN N MS CORTICA L LESION TISSUE. IN AIM 2 WE WILL LEVERAGE TH RESOLUTION OF IN VIVO IMAGING TO DETERMINE THE ABSENCE O MG DURING RECOVERY CHANGES THE FATE OF BASELINE OLS, NEWLY FORMED OLS OR OPCS. WILL ALS DETERMINE, WITH SINGLE CELL RNASEQ, WHETHER CORTICAL EMYELINATION INDUCES DIFFERENTIAL GENE CHANGES IN CORTICAL OPCS THAT COUL IMPAIR THEI ABILITY TO REGENERATE OLS. TOGETHER, THESE AIMS WILL THE REMYELINATION-SPECIFIC ROLE O CORTICAL MG. BASED ON THESE FINDINGS, WE WILL TARGET AND MANIPULATE RAM FEATURES THAT PROMOTE OL REGENERATION AND REMYELINATI ON. C T . . R O K D F O I F L I O H E F O D D R F

Posted 4/15/24, 12:00 AM